期刊
AMERICAN JOURNAL OF HYPERTENSION
卷 30, 期 11, 页码 1049-1052出版社
OXFORD UNIV PRESS
DOI: 10.1093/ajh/hpx054
关键词
blood pressure; cardiac fibrosis; hypertension; hypertensive heart disease; molecular signaling with fibrogenic and fibrolytic axes; myocardial stiffness; myofibroblast secretome
Established cardiac fibrosis (ECF) with symptomatic heart failure preserved ejection fraction represents an ever-increasing segment of the hypertensive population. The regression of ECF with attendant improvement in myocardial stiffness and symptomatic failure represents an unmet health care need. Is the regression of ECF in hypertensive heart disease feasible and will stiffness and symptomatic failure be improved? What is the cellular/molecular signaling involved in its regression? What incremental knowledge is needed to proceed effectively? These issues are addressed in this Review.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据